|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$481,683
|
N/A
|
National Institutes of Health
|
|
ATBC Study
|
ZIA CP010195-03031
|
$1,161,432
|
$92,915
|
N/A
|
DCEG (NCI)
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$2,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$1,200
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$2,373
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$3,991
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$75,854
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101-10336
|
$43,293
|
$2,165
|
Abnet, Christian
|
DCEG (NCI)
|
|
Linxian nutrition intervention trial follow-up study
|
ZIA CP000112-00377
|
$254,770
|
$127,385
|
Abnet, Christian
|
DCEG (NCI)
|
|
Linxian nutrition intervention trials - etiologic studies
|
ZIA CP000112-10339
|
$94,675
|
$47,338
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185-10318
|
$18,664
|
$18,664
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185-10361
|
$31,091
|
$18,654
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Thinker Study
|
ZIA CP000185-10464
|
$10,520
|
$10,520
|
Abnet, Christian
|
DCEG (NCI)
|
|
NCI UNC Project ESCC
|
ZIA CP000185-10779
|
$253,239
|
$253,239
|
Abnet, Christian
|
DCEG (NCI)
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Leveraging polyamine metabolic stress as a novel therapy for prostate cancer
|
4K00CA212455-03
|
$69,749
|
|
AFFRONTI, HAYLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
$1,549
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$1,454
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
$7,372
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
5R01CA172741-05
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
$13,679
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144-07130
|
$2,383,555
|
$47,671
|
Alter, Blanche
|
DCEG (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Oncogenic Disruption of the Circadian Metabolic Cycle in Cancer
|
4R00CA204593-03
|
$249,000
|
|
ALTMAN, BRIAN
|
UNIVERSITY OF ROCHESTER
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
|
1R01CA222931-01A1
|
$370,575
|
|
AMENGUAL, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Functional Contribution of Metabolic Complex to Cancer Cell Metabolism
|
1R03CA219609-01A1
|
$72,194
|
|
AN, SONGON
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
|
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
|
3R01AR070234-04S1
|
$55,691
|
|
ANANDASABAPATHY, NIROSHANA
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Automated, Augmented Reality High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
3R01CA181275-03S1
|
$497,433
|
$497,433
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-04
|
$1,088,646
|
$1,088,646
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Developing Human Induced Pluripotent Stem Cell Precision Oncology Models
|
1R50CA233164-01
|
$155,981
|
|
ANASTASAKI, CORINA
|
WASHINGTON UNIVERSITY
|
Total relevant funding to Esophagus for this search: $34,512,246
|